Articles From: UPDATE: Oracle, Yahoo in focus after hours to Pizza Pizza Royalty Corp. Announces Second Quarter Financial Results


By Benjamin Pimentel, MarketWatch SAN FRANCISCO (MarketWatch) -- Shares of Oracle Corp.
Sign-up for UPDATE: Oracle, Yahoo in focus after hours investment picks
By Benjamin Pimentel, MarketWatch SAN FRANCISCO (MarketWatch) -- Larry Ellison is stepping down as chief executive of Oracle Corp.
Sign-up for Larry Ellison guided Oracle through major shifts in IT investment picks
By Benjamin Pimentel, MarketWatch SAN FRANCISCO (MarketWatch)--Oracle Corp.
Sign-up for UPDATE: What to look for in Oracle's earnings report investment picks
By Benjamin Pimentel, MarketWatch SAN FRANCISCO (MarketWatch) -- Shares of Oracle Corp.
Sign-up for Oracle, Yahoo in focus after hours investment picks
2014/10/3
By Evelyn M.
Sign-up for Yahoo nears investment in Snapchat investment picks
2014/7/17
By Bill Gates Not long after I first met Warren Buffett back in 1991, I asked him to recommend his favorite book about business.
Sign-up for UPDATE: Gates's and Buffett's favorite business book is out of print investment picks
2014/9/15
By Bill Sanderson Rising energy prices and falling costs for electricity-generating solar panels make rooftop solar installations a good way for millions of American homeowners to slash their electric bills.
Sign-up for UPDATE: Want to go solar? Buy the panels investment picks
WHITEHOUSE STATION, N.J. , Sept.
Sign-up for Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA ® (pembrolizumab) – the company’s anti-PD-1 therapy – in PD-L1 positive, advanced gastric cancer.
Sign-up for Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014 investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Sign-up for Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy investment picks
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company’s investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, September 26 – 30.
Sign-up for Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Company’s Investigational Anti-PD-1 Antibody, at ESMO 2014 investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA ® (pembrolizumab) – the company’s anti-PD-1 therapy – in PD-L1 positive, advanced urothelial cancer (also known as bladder cancer). The early findings presented showed a confirmed overall response rate of 24 percent with KEYTRUDA as monotherapy, as measured by RECIST v1.1, central review (n= 7/29: 95% CI, 10.3-43.5) including a complete response rate of 10 percent (3/29). At the time of analysis, response durations ranged from 16+ to 40+ weeks with six of the seven responders continuing on therapy.
Sign-up for Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014 investment picks
2014/10/3
By Blake Z.
Sign-up for UPDATE: Lamborghini reveals 910-hp hybrid Asterion investment picks
2014/10/2
By Blake Z.
Sign-up for Lamborghini reveals 910-hp hybrid Asterion investment picks
Acquisition Unites Manhattan's Integrated Workplace Management System and Computer-Aided Facilities Management Solutions with Trimble's Portfolio of Construction Management, Analytics and Visualization Tools SUNNYVALE, Calif.
Sign-up for Trimble Acquires Manhattan Software to Expand Role in Facilities and Real Estate Management investment picks
NOVATO, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a multiple-dose study, conducted by Kyowa Hakko Kirin Pharma, Inc. (KKP), of the investigational anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness.
Sign-up for Ultragenyx Announces Results From Phase 1/2 Study of KRN23 in X-linked Hypophosphatemia in Adults investment picks
NOVATO, Calif., July 1, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the first patient screened and enrolled in the Phase 2 study of the human monoclonal anti-FGF23 antibody KRN23 (UX023) in pediatric patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness.
Sign-up for Ultragenyx Announces Initiation of a Phase 2 Study of KRN23 for Pediatric X-Linked Hypophosphatemia in the US and EU investment picks
Last Patient Completes 2-Week, Blinded Primary Treatment Period - Top-Line Data on Track to Report in 3Q14 100% of Patients Elected to Continue in 2-Year Open Label Follow-up Period CORAL GABLES, Fla., Aug.
Sign-up for Catalyst Pharmaceutical Partners Provides Updates on Progress of Phase 3 Firdapse Study in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS) investment picks
Treatment with Firdapse achieved statistical significance for both co-primary clinical endpoints CORAL GABLES, Fla., Sept.
Sign-up for Catalyst Pharmaceuticals Announces Positive Top-Line Phase 3 Data From Pivotal Firdapse Clinical Trial in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS) investment picks
- ChromaDex's Patented NIAGEN™ Is the First and Only Commercially Available Nicotinamide Riboside - IRVINE, Calif.
Sign-up for ChromaDex Initiates First Human Clinical Study to Confirm ChromaDex's NIAGEN™ Nicotinamide Riboside Will Increase NAD+ investment picks
By Brad Frischkorn and Chao Deng Asian stocks fell Friday, with Tokyo shares dropping sharply after a selloff in global markets and Australia's benchmark index wiping out its gains for the year.
Sign-up for Asian shares fall after overnight selloffs investment picks
By Brad Frischkorn and Chao Deng Asian stocks fell Friday, with Tokyo shares dropping sharply after a selloff in global markets and Australia's benchmark index wiping out its gains for the year.
Sign-up for UPDATE: Asian shares fall after overnight selloffs investment picks
By Brad Frischkorn and Chao Deng Asian stocks fell Friday, with Tokyo shares dropping sharply after a selloff in global markets and Australia's benchmark index wiping out its gains for the year.
Sign-up for ASIA MARKETS: Asian Shares Fall After Overnight Selloffs investment picks
2014/9/9
By Brad Frischkorn TOKYO -- Asian stock markets were mixed Tuesday as profit-taking and a sharply higher dollar exerted both positive and negative impacts on the region.
Sign-up for Tokyo, Sydney markets end firmer investment picks
2014/9/2
By Bradley Hope The day after Jeffrey Sprecher, the chairman and chief executive of Atlanta's Intercontinental Exchange Inc., took control of the New York Stock Exchange, he sent trusted lieutenant Thomas Farley to size up the 222-year-old icon of capitalism.
Sign-up for Can the New York Stock Exchange be saved? investment picks
2014/8/22
ANN INC.
Sign-up for ANN INC. Reports Second Quarter 2014 Results investment picks
2014/8/22
-- Company Provides Outlook for the Fiscal Third Quarter 2014 --
Sign-up for ANN INC. Reports Second Quarter 2014 Results investment picks
First Quarter Sales Increased 24.3% Over the Same Period a Year Ago to a Record $211.5 Million Driven by Double Digit Growth Across the Major Brands Direct-to-Consumer Comparable Sales Increased 10.0% Over the Same Period a Year Ago Company Raises Fiscal 2015 Outlook GOLETA, Calif.
Sign-up for Deckers Outdoor Corporation Reports First Fiscal Quarter 2015 Financial Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0961618001&sourceType=1 http://www.ccnmatthews.com/logos/20090626-pizzaLogoLG.jpg TORONTO, ONTARIO --
Sign-up for Pizza Pizza Royalty Corp. Announces Second Quarter Financial Results investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: UPDATE: Oracle, Yahoo in focus after hours to Pizza Pizza Royalty Corp. Announces Second Quarter Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices